535 related articles for article (PubMed ID: 19438424)
21. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
Bermejo F; López San Román A; Algaba A; van Domselaar M; Carneros JA; Rivero M; Piqueras B; Valer MP
Gastroenterol Hepatol; 2008 Dec; 31(10):629-32. PubMed ID: 19174078
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
23. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study.
Chow DK; Sung JJ; Tsoi KK; Wong VW; Wu JC; Leong RW; Chan FK
Aliment Pharmacol Ther; 2009 Apr; 29(8):843-54. PubMed ID: 19154567
[TBL] [Abstract][Full Text] [Related]
24. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
Bokemeyer B; Hardt J; Hüppe D; Prenzler A; Conrad S; Düffelmeyer M; Hartmann P; Hoffstadt M; Klugmann T; Schmidt C; Weismüller J; Mittendorf T; Raspe H
J Crohns Colitis; 2013 Jun; 7(5):355-68. PubMed ID: 22503168
[TBL] [Abstract][Full Text] [Related]
25. [Biological therapy as treatment of inflammatory bowel diseases].
Agnholt J
Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
[TBL] [Abstract][Full Text] [Related]
26. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
[TBL] [Abstract][Full Text] [Related]
27. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
28. Use of infliximab in particular clinical settings: management based on current evidence.
Papa A; Mocci G; Bonizzi M; Felice C; Andrisani G; De Vitis I; Guidi L; Gasbarrini A
Am J Gastroenterol; 2009 Jun; 104(6):1575-86. PubMed ID: 19491875
[TBL] [Abstract][Full Text] [Related]
29. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
[TBL] [Abstract][Full Text] [Related]
30. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
31. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
[TBL] [Abstract][Full Text] [Related]
32. Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal.
Regadas FS; Pinto RA; Murad-Regadas SM; Canedo JA; Leal M; Nogueras JJ; Wexner SD
Colorectal Dis; 2011 May; 13(5):555-60. PubMed ID: 20070344
[TBL] [Abstract][Full Text] [Related]
33. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
35. [Optimizing effect of infliximab upon inflammatory bowel disease].
Li SR; Sheng JQ; Li SJ; Zhao XJ
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
[TBL] [Abstract][Full Text] [Related]
36. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration.
Nathan DM; Iser JH; Gibson PR
J Gastroenterol Hepatol; 2008 Jun; 23(6):954-8. PubMed ID: 17559377
[TBL] [Abstract][Full Text] [Related]
37. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
[TBL] [Abstract][Full Text] [Related]
39. [Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab].
Martín De Carpi J; Varea V
An Pediatr (Barc); 2009 Mar; 70(3):271-7. PubMed ID: 19409244
[TBL] [Abstract][Full Text] [Related]
40. Use of corticosteroids, immunomodulators, and infliximab at a third-level Day-Hospital Service of Gastro-Hepatology.
Actis GC; Pellicano R; Bugianesi E; Lagget M; Rizzetto M
Minerva Gastroenterol Dietol; 2008 Sep; 54(3):239-42. PubMed ID: 18614972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
